ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge
- PMID: 22927823
- PMCID: PMC3426556
- DOI: 10.1371/journal.ppat.1002890
ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge
Abstract
Live-attenuated strains of simian immunodeficiency virus (SIV) routinely confer apparent sterilizing immunity against pathogenic SIV challenge in rhesus macaques. Understanding the mechanisms of protection by live-attenuated SIV may provide important insights into the immune responses needed for protection against HIV-1. Here we investigated the development of antibodies that are functional against neutralization-resistant SIV challenge strains, and tested the hypothesis that these antibodies are associated with protection. In the absence of detectable neutralizing antibodies, Env-specific antibody-dependent cell-mediated cytotoxicity (ADCC) emerged by three weeks after inoculation with SIVΔnef, increased progressively over time, and was proportional to SIVΔnef replication. Persistent infection with SIVΔnef elicited significantly higher ADCC titers than immunization with a non-persistent SIV strain that is limited to a single cycle of infection. ADCC titers were higher against viruses matched to the vaccine strain in Env, but were measurable against viruses expressing heterologous Env proteins. In two separate experiments, which took advantage of either the strain-specificity or the time-dependent maturation of immunity to overcome complete protection against SIV(mac)251 challenge, measures of ADCC activity were higher among the SIVΔnef-inoculated macaques that remained uninfected than among those that became infected. These observations show that features of the antibody response elicited by SIVΔnef are consistent with hallmarks of protection by live-attenuated SIV, and reveal an association between Env-specific antibodies that direct ADCC and apparent sterilizing protection by SIVΔnef.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.J Virol. 1995 May;69(5):2737-44. doi: 10.1128/JVI.69.5.2737-2744.1995. J Virol. 1995. PMID: 7707496 Free PMC article.
-
Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.J Virol. 2018 Jan 2;92(2):e01092-17. doi: 10.1128/JVI.01092-17. Print 2018 Jan 15. J Virol. 2018. PMID: 29093095 Free PMC article.
-
Persistent Low-Level Replication of SIVΔnef Drives Maturation of Antibody and CD8 T Cell Responses to Induce Protective Immunity against Vaginal SIV Infection.PLoS Pathog. 2016 Dec 13;12(12):e1006104. doi: 10.1371/journal.ppat.1006104. eCollection 2016 Dec. PLoS Pathog. 2016. PMID: 27959961 Free PMC article.
-
Mechanisms of protection against simian immunodeficiency virus infection.Vaccine. 2002 May 6;20(15):1985-7. doi: 10.1016/s0264-410x(02)00083-x. Vaccine. 2002. PMID: 11983259 Review.
-
Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6.J Intern Med. 2009 Jan;265(1):67-77. doi: 10.1111/j.1365-2796.2008.02051.x. J Intern Med. 2009. PMID: 19093961 Free PMC article. Review.
Cited by
-
Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins.EBioMedicine. 2016 Oct;12:208-218. doi: 10.1016/j.ebiom.2016.09.004. Epub 2016 Sep 9. EBioMedicine. 2016. PMID: 27633463 Free PMC article.
-
Activation of NK cells by HIV-specific ADCC antibodies: role for granulocytes in expressing HIV-1 peptide epitopes.Hum Vaccin Immunother. 2013 May;9(5):1011-8. doi: 10.4161/hv.23446. Epub 2013 Jan 16. Hum Vaccin Immunother. 2013. PMID: 23324623 Free PMC article.
-
Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection.mSphere. 2022 Feb 23;7(1):e0083921. doi: 10.1128/msphere.00839-21. Epub 2022 Feb 23. mSphere. 2022. PMID: 35196125 Free PMC article.
-
Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function.Front Immunol. 2019 Apr 8;10:697. doi: 10.3389/fimmu.2019.00697. eCollection 2019. Front Immunol. 2019. PMID: 31024542 Free PMC article. Review.
-
Transcriptional profiling of peripheral CD8+T cell responses to SIVΔnef and SIVmac251 challenge reveals a link between protective immunity and induction of systemic immunoregulatory mechanisms.Virology. 2014 Nov;468-470:581-591. doi: 10.1016/j.virol.2014.09.013. Epub 2014 Oct 1. Virology. 2014. PMID: 25282469 Free PMC article.
References
-
- Hofmann-Lehmann R, Vlasak J, Williams AL, Chenine AL, McClure HM, et al. (2003) Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 17: 157–166. - PubMed
-
- Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, et al. (1995) Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267: 1820–1825. - PubMed
-
- Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, et al. (1999) Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 5: 194–203. - PubMed
-
- Wyand MS, Manson KH, Lackner AA, Desrosiers RC (1997) Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nat Med 3: 32–36. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- AI063993/AI/NIAID NIH HHS/United States
- RR000168/RR/NCRR NIH HHS/United States
- R01 AI063993/AI/NIAID NIH HHS/United States
- 3P01AI071306-04S1/AI/NIAID NIH HHS/United States
- R01 AI098485/AI/NIAID NIH HHS/United States
- OD01103/OD/NIH HHS/United States
- HHSN261200800001E/CA/NCI NIH HHS/United States
- P51 RR000168/RR/NCRR NIH HHS/United States
- K26 RR000168/RR/NCRR NIH HHS/United States
- HHSN261200800001C/CA/NCI NIH HHS/United States
- AI071306/AI/NIAID NIH HHS/United States
- P01 AI071306/AI/NIAID NIH HHS/United States
- P30 AI060354/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources